dimanche 15 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· January 22, 2026

P&G Announces Fiscal Year 2026 Second Quarter Results

View original at finance.yahoo.com
“Operating cash flow was $5.0 billion, and net earnings were $4.3 billion for the quarter.”
Verbatim excerpt from the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • FX expected to provide $200M after-tax tailwind for FY2026

    80% confidence
  • FY2026 organic sales growth guidance maintained at 0% to +4%

    80% confidence
  • P&G has confidence in plans to deliver stronger results in the second half of fiscal year 2026

    80% confidence
  • P&G's strategy is to reinvent P&G and create the CPG company of the future, delivering long-term balanced top- and bottom-line growth

    80% confidence
  • Commodity costs expected to be neutral for FY2026 (updated from prior forecast)

    80% confidence
  • FY2026 core EPS growth guidance maintained at 0% to +4% (range $6.83 to $7.09)

    80% confidence
  • FY2026 diluted EPS growth revised down to +1% to +6% (from +3% to +9%) due to restructuring charges

    80% confidence
  • Tariff costs expected to create $400M after-tax headwind for FY2026

    80% confidence
  • P&G's Q2 results keep the company on track to deliver within fiscal year guidance ranges for organic sales growth, core EPS growth and adjusted free cash flow productivity in a challenging consumer and geopolitical environment

    80% confidence
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Sources réconciliées : aucun conflit ouvert pour l'instant.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,959
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,959 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
P&G Announces Fiscal Year 2026 Second Quarter Results: Source | Via News | fr.via.news